Biopharma Research, Page 3 | Maven Bio

Skip to main content

The Next Generation of Chronic Spontaneous Urticaria Treatments: Targets, Approvals, and Pipeline Momentum

Dec 23, 2025

Inside Big Pharma Portfolios Part 2: What Drove Revenue in Q3 2025

Dec 22, 2025

Johnson and Johnson Q3 2025 Earnings: Oncology and Immunology Drive Growth After Strategic Reset

Dec 19, 2025

Advancing Beyond Statins: Emerging Cholesterol-Lowering Medicines Reshaping Lipid Management

Dec 17, 2025

AbbVie Q3 2025 Earnings: Skyrizi and Rinvoq Drive Post-Humira Growth

Dec 17, 2025

Market Capitalization Trends of Leading Pharmaceutical Companies in 2025

Dec 17, 2025

Pfizer Q3 2025 Earnings Analysis: Portfolio Rebalancing Amid COVID Decline and Upcoming LOEs

Dec 17, 2025

HER2-Targeted Therapies Across Solid Tumors: Treatment Expansion and Earlier-Line Adoption in 2025

Dec 17, 2025

Merck Q3 2025 Earnings Breakdown: Keytruda Dominance, Vaccine Softness, and Pipeline Diversification

Dec 17, 2025

Research your next biopharma question with Maven.

Request a trial